North Carolina CON Repeal Reshapes Encompass Health's Growth Horizon

Encompass Health’s second-quarter 2026 report was a clean beat: revenue up 9.6%, adjusted EBITDA up 9.2%, and adjusted EPS up 10.7%. Management again raised full-year guidance. But the real news is a regulatory earthquake in North Carolina that fundamentally changes the company’s long-term growth algorithm.

North Carolina: A Blank Sheet of Paper

Last month, the state North Carolina repealed its Certificate of Need (CON) law for inpatient rehabilitation effective October 1. CEO Mark Tarr called it “a great result for the citizens of North Carolina who will now benefit from more access to inpatient rehabilitation care.” The company had been preparing for this moment—its market-by-market analysis (similar to Florida post-repeal) has already prioritized 15 markets and put three real estate parcels under contract. CFO Doug Coltharp elaborated on the strategic importance:

When you're prevailing at almost 90% on these patients, what it tells you is that those patients should have been admitted on the front end into our hospitals.

The company currently operates just one hospital in North Carolina (a JV with Novant in Winston-Salem), so the state is essentially a blank canvas. Coltharp noted, “Given that we only have one hospital in the state of North Carolina and the extensive opportunities that are there, we're essentially starting with a blank sheet of paper.” The initial 15 markets span both large and small towns, and management expects de novo growth to push toward the high end of its 6–10 annual range starting in 2029—potentially exceeding it as small-format hospitals and hub-and-spoke strategies come into play.

This is a company-specific catalyst, not a sector-wide theme. While global keywords around tariffs and IEEPA refunds dominate other healthcare earnings this quarter, Encompass is uniquely exposed to state-level regulatory tailwinds.

Workforce Investment Pays Dividends

The quarter also showcased another strategic lever: career ladder programs. Participation has surged, with 43% of eligible RNs now enrolled. The impact on retention is dramatic—laddered nurses turn over at just 5%, versus 25% for non-laddered peers. Favorable clinical staff turnover translated directly to lower premium labor spend (down $2.6 million YoY) and improved productivity. COO Patrick Tuer highlighted, “we are up to 43% of eligible RNs and certified nurses that are participating on the ladder.” This is not a new theme—management has discussed clinical ladders for several quarters, but the scale of participation and the hard numbers are now crystallizing.

Medicare Advantage: Fighting Back with Data

The company’s admit-and-appeal strategy against Medicare Advantage (MA) denials is gaining traction. In the quarter, 298 patients were admitted under this approach, with an 89% success rate on fully adjudicated cases. Doug Coltharp explained the broader implication:

When you're prevailing at almost 90% on these patients, what it tells you is that those patients should have been admitted on the front end into our hospitals.

This validates the company’s insistence that MA denials were often medically inappropriate. The pilot is now set to scale by diagnosis, with stroke identified as a high-probability category for portfolio-wide rollout.

Financial Strength and Capital Return

Beyond the operational wins, Encompass continues to fortify its balance sheet. Net leverage sits at 1.9x, and the company announced a $1 billion buyback authorization. Operating margin reached 18.2% in Q1 2026, up 180 bps YoY, reflecting continued efficiency gains. The guidance raise—despite absorbing a $11.5M YoY headwind from net provider tax impact—demonstrates underlying momentum. CapEx is running at ~15% of revenue (near a high watermark), but management views this as a reinvestment phase that will ultimately drive double-digit discharge growth.

The change is more than a beat—it’s a structural shift in the company’s growth ceiling. With North Carolina opening up and the workforce model proving scalable, Encompass is positioning itself to outgrow its historical range for years to come.